Umbilical Cord-derived Wharton’s Jelly for Regenerative Medicine Applications in Orthopedic Surgery: A Systematic Review Protocol

Benjamin J. Main  
Beaumont Hospital - Farmington Hills

Josiah A. Valk  
Beaumont Hospital - Farmington Hills

Nicola Maffulli  
Barts and The London School of Medicine and Dentistry

Hugo C. Rodriguez  
University of the Incarnate Word School of Osteopathic Medicine

Manu Gupta  
Future Biologics

Ian W. Stone  
University of the Incarnate Word School of Osteopathic Medicine

Saadiq F. El-Amin III  
Biointegrate

Ashim Gupta (✉️ ashim6786@gmail.com)  
Future Biologics  https://orcid.org/0000-0003-1224-2755

Study protocol

Keywords: Regenerative Medicine, Musculoskeletal Injuries, Umbilical Cord, Wharton's Jelly, PRISMA

DOI: https://doi.org/10.21203/rs.3.rs-34938/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License
Abstract

Background: Musculoskeletal injuries and conditions affect millions of individuals. These ailments are typically managed by immobilization, physiotherapy or activity modification. Regenerative medicine has experienced tremendous growth in the past decades, especially in musculoskeletal medicine. Umbilical cord-derived Wharton’s Jelly is an exciting new option for such therapies. Wharton’s jelly is a connective tissue located within the umbilical cord largely composed of mesenchymal stem cells and extracellular matrix components, including collagen, chondroitin sulfate, hyaluronic acid and sulfated proteoglycans. Wharton’s Jelly is a promising and applicable biologic source for orthopedic regenerative application.

Methods: A systematic search will be conducted in PubMed, ScienceDirect and Google Scholar databases of English, Italian, French, Spanish and Portuguese language articles published to date. References will be screened and assessed for eligibility by two independent reviewers as per PRISMA guidelines. Articles will be considered without exclusion to sex, activity or age. Studies will be included if they used culture-expanded, mesenchymal stem/stromal cells of mesenchymal stem cells and/or connective tissue obtained from Wharton’s Jelly. Studies will be excluded if Wharton’s Jelly is not the sole experimental examined cell type. Placebos, conventional non-operative therapies including steroids injections, exercise and NSAIDs will be compared. The study selection process will be performed independently by two reviewers using a reference software. Data synthesis and meta-analysis will be performed separately for clinical and pre-clinical studies.

Discussion: The results will be published in relevant peer-reviewed scientific journals. Investigators will present results at national or international conferences.

Trial registration: The Protocol will be registered on PROSPERO international prospective register of systematic reviews prior to commencement.

Background

Musculoskeletal conditions affect millions of individuals each year and represent a large burden on healthcare. These ailments are classically managed with immobilization, activity modification, physical therapy, and pharmacological agents, and surgery when conservative management has failed. These modalities are limited, often attempting to limit pain rather than addressing the actual pathology [1–7].

Regenerative medicine has undergone tremendous growth during the past few decades, especially in musculoskeletal medicine [8]. Human stem cells offer regenerative potential, aiming to hasten or reverse chronic disease in order to restore function [9–11]. Common sources of metabolically available human stem cells include bone marrow concentrate (BMC), adipose tissue, amniotic tissue, umbilical cord blood and umbilical cord-derived Wharton’s Jelly [12–17]. Stem cell biologic therapies for the treatment of musculoskeletal injuries are becoming more common in orthopedic clinical practice. Increased patient awareness has led to increased demand for biologic therapies [8].
To date, there is no consensus regarding the most appropriate stem cell source. BMC, PRP, and adipose-derived stem cells (ADSCs) have received increased scientific attention given their unique properties and clinical availability. Direct injection therapy has proven beneficial in a human model. Bone marrow mesenchymal stem cells (BMSCs) have limitations associated with increased pain and morbidity from the bone marrow aspiration procedure [18]. BMC has a limited number of BMSCs, with roughly (0.001–0.01%) of BMSCs within the BMC [18]. The limited availability and the fact that BMSCs show signs of early senescence urge to identify and exploit other sources of stem cells [18]. The literature on ADSCs is limited, with the lack of randomized double-blinded trials and lack of long term follow up observation being the major contributors [19]. The long-term safety of ADSCs is also yet to be determined [19]. PRP has been extensively studied, but most of the results are biased, and from poorly designed studies that favor the publication of positive results [20]. Although safe and promising, PRP still has not shown strong evidence of efficacy and effectiveness in the human clinical setting [20].

Wharton's Jelly is a connective tissue located within the umbilical cord largely composed of hyaluronic acid and chondroitin sulfate. The chief role of Wharton's Jelly is to resist torsional and compressive stresses imposed upon the umbilical vessels during fetal development. Within the Wharton's Jelly are primitive mesenchymal stem cells [21]. These perinatal mesenchymal stem cells resemble embryonic stem cells, but, retain many properties of adult mesenchymal stem cells. Wharton's Jelly-derived mesenchymal stem cells express lower levels of pluripotent markers than embryonic stem cells, suggesting they are highly multipotent rather than pluripotent [22, 23]. Wharton's Jelly contains the highest concentration of mesenchymal stem cells per milliliter compared to other tissues with rich extracellular matrix components, including collagen, chondroitin sulfate, hyaluronic acid, and sulfated proteoglycans [24, 25]. Wharton's Jelly has also a clinically relevant quantity of growth factors, cytokines and extracellular vesicles [1]. The large amount of these substances may play a role in reducing inflammation, pain and augment healing of musculoskeletal injuries [1].

Wharton's Jelly is easily accessible and available as opposed to other biologics. Every birth presents an opportunity to harvest these highly multipotent, nutrient rich mesenchymal stem cells. The ease of collection offers many advantages over current BMC and adipose-derived stem cell harvest, which pose donor site morbidity. This factor, as well as the attractive expansion properties of umbilical-derived stem cells and clinically significant amounts of applicable regenerative substances, make Wharton's Jelly a promising source of mesenchymal stem cells for orthopedic regenerative application [1, 26]. Considering the lack of clarity regarding the use of Wharton's jelly, methodological factors, clinical translation and outcome measurement, a systematic review is required to synthesize and evaluate the quality of the available evidence regarding the safety and efficacy of Wharton's jelly for regenerative medicine applications in orthopedic surgery. The primary objective of this review is to report the clinical, structural and functional outcomes of the applications of Wharton's jelly for regenerative medicine in orthopedic surgery. The secondary objective is to identify methodological characteristics associated with application outcomes.
Methods

The protocol will be registered on the PROSPERO international prospective register of systematic reviews. The systematic review will follow the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement and guidelines [27, 28].

Eligibility Criteria

The PICOS (Population, Intervention, Comparison, Outcome, Study Design) framework will be used as a template for defining eligibility criteria for literature search [29]. Characteristics for clinical studies are as follow:

Population

Research involving animal and human models (clinical studies as well as in vitro research) will be considered for review, without exclusion relating to sex or age. Basic science studies must include human cells isolated from a living model. Studies meeting eligibility criteria will apply to acute orthopedic musculoskeletal injury, chronic orthopedic musculoskeletal conditions, or an artificial disease model. Articles will be excluded if they do not relate to orthopedic intervention.

Intervention

Research meeting inclusion criteria will involve the use of mesenchymal stem cells and/or connective tissue obtained from Wharton's Jelly. Studies will be excluded if Wharton's Jelly is not the experimental examined cell type. Studies involving umbilical derived stem cells will be excluded unless the study specifies the use of Wharton's Jelly. Studies will be excluded if they report the use of Wharton's Jelly derived mesenchymal stem cells in combination with other cell populations.

Comparison

Comparators considered will include placebos, non-injury models, acute injury models, non-injury models, and gold standard treatments for orthopedic injury.

Outcomes

For basic scientific research, studies relating to human musculoskeletal injury via histological or biochemical measures will be included. For clinical research, studies pertaining to human or animal orthopedic musculoskeletal injury via histological and/or biochemical measures and functional scores (pain, activity, quality of life, etc.) will be included.

Study Design

Observational studies (cohort, cross-sectional and case-controlled prospective or retrospective studies) or randomized controlled trials comparing outcomes of connective tissue derived from Wharton's Jelly with control, experimental therapy, or gold standard treatment at any follow up period will be included. Systematic reviews will only be examined to identify further studies for inclusion, and results of meta-
analysis will not be included in the analysis. With regard to publication year, all studies published to date will be included.

**Information Sources**

A systematic search will be conducted in PubMed, ScienceDirect and Google Scholar databases of English, Italian, French, Spanish and Portuguese language articles published before May 2020. Secondary searching of reference lists of key articles and reviews will be undertaken to identify any additional studies potentially missed in electronic search.

**Search**

The search and selection process will be based on the PRISMA checklist and flow diagram based on the eligibility and inclusion criteria previously outlined. A web-based reference software system (RefWorks) will be used for data management.

**Study Selection**

The study selection process will be performed independently by two reviewers. Screening of abstracts will be performed, and full text articles will be retrieved and uploaded to the reference software. A thorough secondary screening will be performed independently by two reviewers. The secondary screening of the full text articles will eliminate studies that do not meet inclusion criteria.

**Data Collection**

Data extraction from articles that meet inclusion criteria will be performed by two independent reviewers. Data extracted and synthesized will include authors, publication year, study design, group controls, group interventions, outcome measurement, and outcome assessment. Customized forms will be used in the data extraction and collection process. The primary authors will be contacted via email for any information necessitating clarification.

**Data Items**

Relevant items of population, problem, intervention, comparison, and outcome will be extracted and included. For basic scientific research, relevant histological and/or biochemical measures will be included. For clinical research, all histological measures, biochemical measures and functional scores will be included.

**Risk of bias**

Multiple tools will be used to assess the risk of bias for included studies. The Systematic Review Centre for Laboratory Animal Experimentation (SYRCLE) risk of bias tool will be applied to animal studies [30]. Ten domains will be addressed related to selection bias, performance bias, detection bias, attrition bias, reporting bias, and other biases. The Risk Of Bias In Non-randomized Studies of Interventions (ROBINS-I) tool will be used to assess observational and quasi-randomized studies [31]. Seven domains will be utilized to assess risk including: confounding, participant selection bias, classification bias, deviation
bias, bias due to missing data, outcome measurement bias, and bias in selection of reported results. Studies will be judged to have no information or a low, moderate, serious, or critical risk of bias. For randomized control trials, the Risk of Bias 2 (RoB 2) tool will be used to establish risk of bias [32]. Five domains including biases arising from the randomization process, due to deviations from intended interventions, due to missing outcome data, in measurement of the outcome, and in selection of the reported result will be analyzed. Overall risk of bias will be determined to be low, some concerns, or high. All included studies will be independently scored by two reviewers, and consensus reached by discussion.

Data synthesis and meta-analysis

Data synthesis and meta-analysis will be performed separately for clinical and pre-clinical studies, following the guidelines published by Hooijmans et al [30]. Given the sparsity of homogenous research, a qualitative analysis of common outcome variables will be conducted. Subgroups chosen for analysis will include cells derived from Wharton’s Jelly versus experimental therapy and/or control. Results of meta-analyses extracted data will be summarized in tables and narrative interpretation provided, with emphasis on outcome measures.

Discussion

The results of this review will be published in a relevant scientific journal or presented at national or international conferences (’Publications’) by the Investigators.

Documenting Protocol Amendments

Protocol amendments and updates will be documented via PROSPERO online register. The nature of the changes made will be recorded, dated and accessible along with the most recent version within the record audit trail under the systematic review protocol registration.

List Of Abbreviations

ADSCs Adipose-derived stem cells

BMC Bone marrow concentrate

BMSCs Bone marrow mesenchymal stem cells

PICOS Population, Intervention, Comparison and Outcome

PRISMA Preferred Reporting Items for Systematic Reviews and Meta-Analyses

PRP Platelet-rich plasma

ROBINS-I Risk Of Bias in Non-randomized Studies- of Interventions
Declarations

Ethics approval and consent to participate

Not applicable

Consent for publication

Not applicable

Availability of data and materials

The results of this review will be published in a relevant scientific journal or presented at national or international conferences (‘Publications’) by the Investigators.

Competing interests

The authors declare that they have no competing interests.

Funding

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Authors’ contributions

AG and NM contributed to the review concept and study design. BJM, JAV and AG provided input for the review. BJM and JAV provided input to the development of search strategies and methodologies for the literature review. BJM, JAV, HCR, MG, IWS, NM, SFE and AG drafted the review protocol. All authors provided feedback and approved the final protocol. AG is the guarantor of the review.

Acknowledgments

Not Applicable

References

1. Gupta A, El-Armin SF 3rd., Levy HJ, Sze-Tu R, Ibim SE, Maffulli N. Umbilical cord-derived Wharton’s jelly for regenerative medicine applications. J Orthop Surg Res. 2020 Feb;15(1):49.

2. Navani A, Manchikanti L, Albers SL, Latchaw RE, Sanapati J, Kaye AD, et al. Responsible, Safe, and Effective Use of Biologics in Management of Low Back Pain: American Society of Interventional Pain Physicians (ASIPP) Guidelines, et al. Pain Physician. 2019 Jan;22(1 s):1–74.
3. Gupta A, Woods MD, Illingworth KD, Niemeier R, Schafer I, Cady C, et al. Single walled carbon nanotube composites for bone tissue engineering. J Orthop Res. 2013 Sep;31(9):1374–81.

4. Gupta A, Main BJ, Taylor BL, Gupta M, Whitworth CA, Cady C, et al. In vitro evaluation of three-dimensional single-walled carbon nanotube composites for bone tissue engineering. J Biomed Mater Res A. 2014 Nov;102(11):4118–26.

5. Gupta A, Liberati TA, Verhulst SJ, Main BJ, Roberts MH, Potty AG, et al. Biocompatibility of single-walled carbon nanotube composites for bone regeneration. Bone Joint Res. 2015 May;4(5):70–7.

6. Vallejo R, Gupta A, Kelly CA, Vallejo A, Rink J, Williams JM, et al. Effects of Phase Polarity and Charge Balance Spinal Cord Stimulation on Behavior and Gene Expression in a Rat Model of Neuropathic Pain. Neuromodulation. 2020 Jan;23(1):26–35.

7. Gupta A, Sharif K, Walters M, Woods MD, Potty A, Main BJ, et al. Surgical retrieval, isolation and in vitro expansion of human anterior cruciate ligament-derived cells for tissue engineering applications. J Vis Exp. 2014 Apr 30;(86).

8. Lamplot JD, Rodeo SA, Brophy RH. A practical Guide for the Current Use of Biologic Therapies in Sports Medicine. Am J Sports Med. 2020 Feb;48(2):488–503.

9. Caplan Al. Mesenchymal stem cells. J Ortho Res. 1991 Sep;9(5):641–50.

10. Minguell JJ, Erices A, Conget P. Exp Biol Med (Maywood). 2001 Jun;226(6):507–20.

11. Andia I, Maffulli N. New biotechnologies for musculoskeletal injuries. Surgeon. 2019 Aug;17(4):244–255.

12. Le ADK, Enweze L, DeBaun MR, Dragoo JL. Current Clinical Recommendations for Use of Platelet-Rich Plasma. Curr Rev Musculoskelet Med. 2018 Dec;11(4):624–34.

13. Patel JM, Saleh KS, Burdick JA, Mauck RL. Bioactive factors for cartilage repair and regenerations: Improving delivery, retention, and activity. Acta Biomater. 2019 Jul 15;93:222–238.

14. Le ADK, Enweze L, DeBaun MR, Dragoo JL. Platelet-rich Plasma. Clin Sports Med. 2019 Jan;38(1):17–44.

15. Sezgin EA, Atik OS. Are orthobiologics the next chapter in clinical orthopedics? A literature review. Eklem Hastalik Cerrahisi. 2018 Aug;29(2):110–6.

16. Duerr RA, Ackermann J, Gomoll AH. Amniotic-Derived Treatments and Formulations. Clin Sports Med. 2019 Jan;38(1):45–59.

17. Chirichella PS, Jpw S, Iacono S, Wey HE, Malanga GA. Treatment of Knee Meniscus Pathology: Rehabilitation, Surgery, and Orthobiologics. PM R. 2019 Mar;11(3):292–308.

18. Mohamed-Ahmed S, Fristad I, Lie SA, Suliman S, Mustafa K, Vindenes H, et al. Adipose-derived and bone marrow mesenchymal stem cells: a donor-match comparison. Stem Cell Res Ther. 2019;168(9).

19. Usuelli FG, D’Ambrosi R, Maccario C, Indino C, Manzi L, Maffulli N. Adipose-derived stem cells in orthopaedic pathologies. Br Med Bull. 2017;Dec1;124(1):31–54.

20. Brossi PM, Moreira JJ, Machado TS, Baccarin RY. Platelet-rich plasma in orthopedic therapy: a comparative systematic review of clinical and experimental data in equine and human
musculoskeletal lesions. BMC Vet Res. 2015 Apr 22;11:98.

21. Troyer DL, Weiss ML. Concise review: Wharton's jelly-derived cells are a primitive stromal cell population. Stem Cells. 2008;26(3):591e9.

22. Carlin R, Davis D, Weiss M, Schultz B, Troyer D. Expression of early transcription factors Oct-4, Sox-2 and Nanog by porcine umbilical cord (PUC) matrix cells. Reproductive Biology Endocrinology. 2006;4(1):8.

23. La Rocca G, Anzalone R, Corrao S, Magno F, Loria T, Lo Iacono M, et al. Isolation and characterization of Oct-4β/HLA-Gβ mesenchymal stem cells from human umbilical cord matrix: differentiation potential and detection of new markers. Histochem Cell Biol. 2009;131(2):267e82.

24. Vangsness CT Jr, Sternberg H, Harris L. Umbilical cord tissue offers the greatest number of harvestable Mesenchymal stem cells for research and clinical application: a literature review of different harvest sites. Arthroscopy. 2015;31:1836–43.

25. Sobolewski K, Małkowski A, Bańkowski E, Jaworski S. Wharton's jelly as a reservoir of peptide growth factors. Placenta. 2005;26:747–52.

26. Schugar RC, Chirieleison SM, Wescoe KE, Schmidt BT, Askew Y, Nance JJ, et al. High harvest yield, high expansion, and phenotype stability of CD146 mesenchymal stromal cells from whole primitive human umbilical cord tissue. Journal of Biomedicine and Biotechnology; 2009. Article ID 789526:11.

27. The PRISMA Group

   Moher D, Liberati A, Tetzlaff J, Altman DG. The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. Open Med 2009; 3(3); 123–130.

28. 10.1136/bmj.b2700

   Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, et al. (2009) The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration. BMJ 2009;339:b2700, doi: 10.1136/bmj.b2700.

29. O'Connor D, Green S, Higgins J. Defining the review question and developing criteria for including studies, Cochrane handbook for systematic reviews of interventions: Cochrane book series, Chichester, West Sussex:Wiley;2008.p. 81–94.ISBN: 978-0-470-51845-8.

30. Hooijmans CR, Rovers MM, de Vries RB, Leenaars M, Ritskes-Hoitinga M, Langendam MW. SYRCLE's risk of bias tool for animal studies. BMC Med Res Methodol. 2014 Mar;26:14:43.

31. Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomized studies of interventions. BMJ. 2016 Oct;12:355:i4919.

32. Sterne JAC, Savović J, Paige MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2 a Revised tool for assessing risk of bias in randomised trials. BMJ. 2019 Aug;28:366:i4898.